StreetAlpha
Acumen Pharmaceuticals, Inc. · SEC Form 4

ABOS Insider Trading

From SEC Form 431 trades in 2 yearsUpdated Nov 19, 2026

Every open market buy and sale of Acumen Pharmaceuticals, Inc. stock by its officers, directors and 10% owners over the last two years, straight from SEC Form 4 filings. Insiders are only selling over the last 12 months: $0 bought and $626K sold.

← ABOS stock page

Insiders are only selling
Bought, 12 months$00 buys · 0 insiders
Sold, 12 months$626K21 sales · 9 insiders
Net−$626Kbought minus sold
Planned sales14%of sold value, 10b5-1 plans

Buying and selling by month

open market, last 12 months
Dec2026-01: sold $501KJan2026-02: sold $28KFeb2026-03: sold $7KMarAprMay2026-06: sold $90KJunJulAugSepOctNov
Bought (up)Sold (down)
AI Pro · insider alerts

Get an alert when ABOS insiders trade

We read every Form 4 the moment the SEC posts it and tell you when an ABOS officer, director or 10% owner buys on the open market, or sells $250K or more outside a pre-arranged plan, by email or on your phone.

Insider alerts are part of AI Pro. Start with a free account, then add AI Pro when you want the alerts.

Every ABOS insider trade

2 years · newest first
InsiderTypePriceHeld afterFiled
Jun 17, 2026Derrell PorterDirectorSale32,300$2.33$75K35,500Jun 17Form 4
Jun 9, 2026Nathan B FountainDirectorSale6,400$2.23$14K48,150Jun 10Form 4
Mar 6, 2026Derek M MeisnerChief Legal Officer & Corp SecSale plan2,090$3.26$7K173,999Mar 10Form 4
Feb 27, 2026Derek M MeisnerChief Legal Officer & Corp SecSale plan9,406$3.01$28K173,999Mar 3Form 4
Jan 28, 2026Derek M MeisnerChief Legal Officer & Corp SecSale plan17,756$3.00$53K173,999Jan 28Form 4
Jan 23, 2026Derek M MeisnerChief Legal Officer & Corp SecSale8,934$1.87$17K173,999Jan 23Form 4
Jan 22, 2026Russell BartonCOOSale2,777$1.81$5K205,092Jan 23Form 4
Jan 22, 2026Daniel Joseph OConnellCEOSale12,035$1.83$22K881,275Jan 23Form 4
Jan 22, 2026Matt ZugaCFO & Chief Business OfficerSale4,160$1.83$8K304,924Jan 23Form 4
Jan 22, 2026Eric SiemersChief Medical OfficerSale3,226$1.81$6K255,371Jan 23Form 4
Jan 12, 2026Daniel Joseph OConnellCEOSale26,472$1.77$47K593,510Jan 12Form 4
Jan 12, 2026Derek M MeisnerChief Legal Officer & Corp SecSale50,659$1.80$91K83,800Jan 12Form 4
Jan 8, 2026Russell BartonCOOSale3,530$1.86$7K123,269Jan 12Form 4
Jan 8, 2026Matt ZugaCFO & Chief Business OfficerSale6,888$1.82$13K209,951Jan 12Form 4
Jan 8, 2026James J. DohertyPresident and CDOSale8,167$1.86$15K54,033Jan 9Form 4
🔒 16 more trades. Create a free account or sign in to see them all.

ABOS insider trading FAQ

Are ABOS insiders buying or selling?

Insiders are only selling over the last 12 months. 0 insiders bought $0 of ABOS on the open market in 0 trades, and 9 sold $626K in 21 trades, 14% of that under pre-arranged trading plans.

When did an ABOS insider last buy shares?

There has been no open market insider purchase of ABOS in the last two years.

When did an ABOS insider last sell shares?

Derrell Porter (Director) sold 32,300 shares for $75K on Jun 17, 2026.

What is a Form 4?

Company officers, directors and owners of more than 10% of the shares must report trades in the company's stock to the SEC on Form 4 within two business days. This page shows open market buys and sales only. Option exercises, stock awards, gifts and shares withheld for taxes are left out, since they are not decisions to buy or sell.

Why do insider sales matter less than buys?

Insiders sell for many reasons, such as taxes, diversification or a home purchase, and many sales are scheduled months ahead under a 10b5-1 trading plan. They buy on the open market mostly when they expect the shares to rise, which is why buying, and especially several insiders buying together, gets more attention.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Trades come from SEC Form 4 filings as reported by the insiders. Insiders have two business days to report, so a trade can be a few days old when it appears. See all insider cluster buys.

From SEC Form 4 filings · Not investment advice